---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-073558"
form_type: "8-K"
ticker: null
cik: "0001492674"
company_name: "T2 Biosystems, Inc."
filed_at: "2025-04-07T23:59:59+00:00"
generated_at: "2026-05-23T19:34:41.928816+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# T2 Biosystems loses entire board and top management; appoints turnaround specialist as CEO

## Summary
- Directors John Sperzel and Robin Toft resigned March 31; Cumming, Elsbree, Toft, Liebman, Adams resigned April 3.
- Michael Gibbs resigned as SVP/GC/Secretary March 18; John Sperzel as CEO/President March 31; John Sprague as CFO/Treasurer April 3.
- Board appointed Craig Jalbert as CEO, President, Treasurer, Secretary, and Class I director effective April 3, 2025.
- Jalbert is a principal at Verdolino & Lowey, P.C., focusing on distressed businesses; compensated $50,000/year.

## SEC filing metadata
- accession: 0001193125-25-073558
- form_type: 8-K
- cik: 0001492674
- company_name: T2 Biosystems, Inc.
- filed_at: 2025-04-07T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1492674/000119312525073558/0001193125-25-073558-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1492674/000119312525073558/d919843d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-073558
- JSON: https://secwatch.observer/filing/0001193125-25-073558.json
- Plain text: https://secwatch.observer/filing/0001193125-25-073558.txt

## Key facts
- Executive change
  Michael Gibbs resigned as Senior Vice President, General Counsel and Corporate Secretary at T2 Biosystems, Inc..
  - Action: resigned
  - Role: Senior Vice President, General Counsel and Corporate Secretary
  source text: On March 18, 2025, Michael Gibbs notified the Company of his termination of that certain Consulting Agreement between himself and the Company, dated February 15, 2025 and his resignation from his position as the Company’s Senior Vice President, General Counsel and Corporate Secretary.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492674/000119312525073558/0001193125-25-073558-index.htm
- Executive change
  Laura Adams resigned as Director at T2 Biosystems, Inc..
  - Action: resigned
  - Role: Director
  source text: On April 3, 2025, John W. Cumming, David Elsbree, Robin Toft, Seymour Liebman and Laura Adams each notified the Company of their respective resignations as members of the Company’s Board and all committees thereof, effective as of 2;25 p.m on April 3, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492674/000119312525073558/0001193125-25-073558-index.htm
- Executive change
  John Sperzel resigned as Chief Executive Officer and President at T2 Biosystems, Inc..
  - Action: resigned
  - Role: Chief Executive Officer and President
  source text: On March 31, 2025, John Sperzel notified the Company of his termination of that certain Consulting Agreement between himself and the Company, dated February 15, 2025 and his resignation from his position as the Company’s Chief Executive Officer and President.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492674/000119312525073558/0001193125-25-073558-index.htm
- Executive change
  John W. Cumming resigned as Director at T2 Biosystems, Inc..
  - Action: resigned
  - Role: Director
  source text: On April 3, 2025, John W. Cumming, David Elsbree, Robin Toft, Seymour Liebman and Laura Adams each notified the Company of their respective resignations as members of the Company’s Board and all committees thereof, effective as of 2;25 p.m on April 3, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492674/000119312525073558/0001193125-25-073558-index.htm
- Executive change
  Robin Toft resigned as Director at T2 Biosystems, Inc..
  - Action: resigned
  - Role: Director
  source text: On March 31, 2025, John Sperzel and Robin Toft each notified T2 Biosystems, Inc. (the “Company”) of their respective resignations as members of the Company’s board of directors (the “Board”) and all committees thereof, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492674/000119312525073558/0001193125-25-073558-index.htm
- Executive change
  Seymour Liebman resigned as Director at T2 Biosystems, Inc..
  - Action: resigned
  - Role: Director
  source text: On April 3, 2025, John W. Cumming, David Elsbree, Robin Toft, Seymour Liebman and Laura Adams each notified the Company of their respective resignations as members of the Company’s Board and all committees thereof, effective as of 2;25 p.m on April 3, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492674/000119312525073558/0001193125-25-073558-index.htm
- Executive change
  David Elsbree resigned as Director at T2 Biosystems, Inc..
  - Action: resigned
  - Role: Director
  source text: On April 3, 2025, John W. Cumming, David Elsbree, Robin Toft, Seymour Liebman and Laura Adams each notified the Company of their respective resignations as members of the Company’s Board and all committees thereof, effective as of 2;25 p.m on April 3, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492674/000119312525073558/0001193125-25-073558-index.htm
- Executive change
  John Sprague resigned as Chief Financial Officer and Corporate Treasurer at T2 Biosystems, Inc..
  - Action: resigned
  - Role: Chief Financial Officer and Corporate Treasurer
  source text: On April 3, 2025, John Sprague notified the Company of his resignation from his position as the Company’s Chief Financial Officer and Corporate Treasurer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492674/000119312525073558/0001193125-25-073558-index.htm
- Executive change
  John Sperzel resigned as Director at T2 Biosystems, Inc..
  - Action: resigned
  - Role: Director
  source text: On March 31, 2025, John Sperzel and Robin Toft each notified T2 Biosystems, Inc. (the “Company”) of their respective resignations as members of the Company’s board of directors (the “Board”) and all committees thereof, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492674/000119312525073558/0001193125-25-073558-index.htm
- Executive change
  Craig R. Jalbert was appointed as Class I Director at T2 Biosystems, Inc..
  - Action: appointed
  - Role: Class I Director
  source text: On April 3, 2025, the Board appointed Craig R. Jalbert, age 63, as a Class I director and the Company’s Chief Executive Officer, President, Corporate Treasurer, and Corporate Secretary, effective as of 11:30 a.m. on April 3, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492674/000119312525073558/0001193125-25-073558-index.htm
- Executive change
  Craig R. Jalbert was appointed as Chief Executive Officer, President, Corporate Treasurer and Corporate Secretary at T2 Biosystems, Inc..
  - Action: appointed
  - Role: Chief Executive Officer, President, Corporate Treasurer and Corporate Secretary
  source text: On April 3, 2025, the Board appointed Craig R. Jalbert, age 63, as a Class I director and the Company’s Chief Executive Officer, President, Corporate Treasurer, and Corporate Secretary, effective as of 11:30 a.m. on April 3, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492674/000119312525073558/0001193125-25-073558-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.